Osteoblast-Derived Lipocalin-2 Regulated by miRNA-96-5p/Foxo1 Advances the Progression of Alzheimer’s Disease
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Aim: Alzheimer’s disease (AD) is the most frequent cause of dementia and characterized by the accumulation of β-amyloid peptides in plaques and vessel walls. This study proposed a hypothesis of an inhibitory role of miR-96-5p in AD via regulating Foxo1. Methods & methods: AD mouse models were established by injecting with 1% pentobarbital. Results: Knockdown of miR-96-5p in the presence of naringin was shown to reduce the expression of Foxo1 and contents of superoxide dismutase, catalase and glutathione peroxidase, yet increase lipocalin-2 expression as well as hydroxyproline and malondialdehyde contents. Also, Foxo1-mediated lipocalin-2 inhibition attenuated AD. Conclusion: Our study shows downregulating miR-96-5p limited AD progression, highlighting miR-96-5p a potential therapeutic target in treating AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“LCN2 and sclerostin aggravate neuroinflammation and abolish synaptic plasticity,304,305 thereby accelerating the progression of AD, PD and ALS.306–308”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [308]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 31 · Cited by 20
Metadata
- Authors
- Wu, B.-W., Guo, J.-D., Wu, M.-S., Liu, Y., Lu, M., Zhou, Y.-H., & Han, H.-W.
- Affiliations
- Department of Biochemistry, Basic Medicine College, Hebei University of Chinese Medicine, Shijiazhuang050200, Hebei Province, PR China
- Hebei University of Chinese Medicine (CN)
- Hebei Key Laboratory of Chinese Medicine Research on Cardio-Cerebrovascular Disease, Shijiazhuang050091, Hebei Province, PR China
- ORCID
- Venue
- Epigenomics
- Publisher
- Informa UK Limited
- Published
- 2020-09
- Volume
- 12
- Issue
- 17
- Pages
- 1501-1513
- ISSN
- 1750-1911 (ISSN-L)
- 1750-192X
- OpenAlex
- W3083904160
- Cited by
- 20
- References
- 31
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 2 · 2022: 6 · 2021: 4 · 2020: 1
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Epigenomics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Key Scientific and Technological Research Projects of Colleges and Universities in Hebei Province (ZD2019129)
- Research and Research Ability Construction of Traditional Chinese Medicine Resources and Research on Classical Chinese Medicine Documents and Inheritance Schools (21810027)
- Hebei University of Traditional Chinese Medicine
- Hebei Key Laboratory of Chinese Medicine Research on Cardio-Cerebrovascular Disease, Master’s Degree Innovation Funding Project of Hebei Province (CXZZSS2020075)
- , Key R&D Plan of Provincial Science and Technology Plan of Science and Technology Department of Hebei Province in 2019 (19277720D)
- Scientific and Technological Ability of Hebei University of Traditional Chinese Medicine in 2019 (KTZ2019017)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, miR-96-5p, FOXO1, neutrophil gelatinase-associated lipocalin, osteoblasts, oxidative stress, antioxidant enzymes, naringin, therapeutic target
- MeSH terms
- Lipocalin-2, Forkhead Box Protein O1, Alzheimer Disease, Animals, Disease Models, Animal, Disease Susceptibility, Gene Expression Regulation, Osteoblasts, Biomarkers, Disease Progression, RNA Interference, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Osteoblast-Derived Lipocalin-2 Regulated by miRNA-96-5p/Foxo1 Advances the Progression of Alzheimer’s Disease. https://app.cochat.ai/papers/10.2217/epi-2019-0215
- The paper
- Wu, B.-W., Guo, J.-D., Wu, M.-S., Liu, Y., Lu, M., Zhou, Y.-H., & Han, H.-W. (2020). Osteoblast-Derived Lipocalin-2 Regulated by miRNA-96-5p/Foxo1 Advances the Progression of Alzheimer’s Disease. Epigenomics. https://doi.org/10.2217/epi-2019-0215
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.